Want to see GB:OPTI full AI Analyst Report?
OptiBiotix Health (OPTI) AI Stock Analysis
Top Page
OptiBiotix Health
(LSE:OPTI)
The score is held back primarily by persistent losses and continued cash burn despite improving gross margins and strong recent revenue growth. Technicals are broadly neutral with only modest positive momentum, while valuation is constrained by negative earnings and no stated dividend yield.
OptiBiotix Health (OPTI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 5.99M
- Dividend Yield
- ―
- Average Volume (3M)
- 172.56K
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- 0.43
- Revenue Growth
- 11.90%
- EPS Growth
- -2864.29%
- Country
- UK
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
OptiBiotix Health Business Overview & Revenue Model
Company Description
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and...
How the Company Makes Money
OptiBiotix primarily makes money by commercialising its probiotic and microbiome-related intellectual property through business-to-business arrangements rather than operating as a large-scale consumer brand owner. Key revenue streams include: (1) Ing...
OptiBiotix Health Financial Statement Overview
Summary
Strong recent revenue growth and improving gross margin are positives, and the balance sheet has no reported debt. However, the company remains materially unprofitable with widening losses and persistently negative operating cash flow, keeping dilution/financing risk elevated.
Income Statement
34NegativeBalance Sheet
63PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29M | 1.17M | 870.00K | 644.00K | 457.00K | 2.21M |
| Gross Profit | 586.00K | 614.00K | 331.00K | 320.00K | 244.00K | 1.12M |
| EBITDA | -2.24M | -2.93M | -2.06M | -1.84M | 2.75M | 6.51M |
| Net Income | -4.29M | -3.89M | -1.80M | -2.04M | 2.59M | 6.26M |
Balance Sheet | ||||||
| Total Assets | 5.17M | 6.89M | 9.04M | 9.40M | 11.55M | 20.14M |
| Cash, Cash Equivalents and Short-Term Investments | 989.00K | 1.04M | 739.00K | 635.00K | 1.05M | 2.01M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 819.36K |
| Total Liabilities | 442.00K | 610.00K | 647.00K | 532.00K | 643.00K | 1.97M |
| Stockholders Equity | 4.73M | 6.28M | 8.40M | 8.87M | 10.90M | 18.14M |
Cash Flow | ||||||
| Free Cash Flow | -834.00K | -1.77M | -1.77M | -1.53M | -1.28M | -1.76M |
| Operating Cash Flow | -1.71M | -1.77M | -1.77M | -1.53M | -1.11M | -1.56M |
| Investing Cash Flow | 1.40M | 1.35M | 587.00K | 1.11M | -331.00K | -193.51K |
| Financing Cash Flow | 0 | 713.00K | 1.28M | 0 | 485.00K | 2.90M |
OptiBiotix Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OPTI, the sentiment is Neutral. The current price of 5.80 is above the 20-day moving average (MA) of 5.74, below the 50-day MA of 5.84, and below the 200-day MA of 5.96, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 54.15 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:OPTI.
OptiBiotix Health Peers Comparison
Overall Rating
GB:SBTX59Neutral- GB:OPTI47Neutral
GB:TCF42Neutral
GB:CIZ38Underperform
GB:NFX38Underperform
GB:FUM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:SBTX | 59Neutral | GBP 13.61M | -29.17 | -5.25% | ― | 95.16% | 85.60% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:OPTI | 47Neutral | GBP 5.99M | -1.40 | -77.85% | ― | 11.90% | -2864.29% |
| GB:TCF | 42Neutral | GBP 4.64M | -1.70 | -93.92% | ― | ― | 55.56% |
| GB:CIZ | 38Underperform | GBP 5.28M | -6.88 | 192.61% | ― | ― | 42.86% |
| GB:NFX | 38Underperform | GBP 2.74M | -2.23 | -83.53% | ― | ― | 93.02% |
| GB:FUM | 37Underperform | GBP 2.59M | -0.28 | -152.41% | ― | -70.77% | 60.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:OPTI | OptiBiotix Health | 5.80 | -2.20 | -27.50% | |
| GB:TCF | Evgen Pharma | 0.17 | -0.04 | -19.05% | |
| GB:FUM | Futura Medical | 0.17 | -2.43 | -93.27% | |
| GB:NFX | Nuformix Plc | 0.10 | -0.38 | -78.35% | |
| GB:CIZ | Cizzle Biotechnology Holdings PLC | 1.10 | -0.60 | -35.29% | |
| GB:SBTX | SkinBioTherapeutics plc | 5.25 | -10.88 | -67.44% |
OptiBiotix Health Corporate Events
OptiBiotix boosts H1 sales, cuts costs and secures new SlimBiome deals
PositiveOptiBiotix Health reported a 21.9% rise in first-half 2026 revenues to £679,000 and a 25.4% increase in gross profit, while cutting selling, R&D and operating costs and lifting margins. Strong growth in Asia and other Rest of World markets o...
OptiBiotix adds taste industry veteran to drive SweetBiotix push
PositiveOptiBiotix Health has appointed industry veteran Imad Farhat as a non-executive director of its wholly owned subsidiary OptiBiotix Ltd, which houses the SlimBiome, SweetBiotix and microbiome modulating technology platforms. Farhat brings more than th...
OptiBiotix advances SweetBiotix sugar substitute toward commercial production
PositiveOptiBiotix Health has provided an update on its SweetBiotix range, a portfolio of sweet fibres designed to act as healthy sugar substitutes while supporting gut health. The business aims to leverage these microbiome-focused sweeteners to capture dema...
OptiBiotix Taps GLP-1 Boom With Holland & Barrett FORMI Launch
PositiveOptiBiotix Health has expanded its presence in the weight management segment through the launch of Holland & Barrett’s new FORMI Weight Loss Complex, which contains its clinically validated SlimBiome formulation. The product, sold as raspbe...
OptiBiotix to brief investors after SweetBiotix sampling success
PositiveOptiBiotix Health will host a live investor presentation and Q&A on 2 July 2026 via its Investor Hub, following successful SweetBiotix sampling on 24 June. Chief executive Stephen O’Hara will update investors on the commercial progress of f...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026